The 26S proteasome is the primary site for protein degradation in mammalian cells and is critical in cell regulation, protein quality control, and antigen presentation. Although proteasome inhibitors are widely used as research tools and in treatment of certain cancers, the mechanisms by which proteasomes catalyze the ATP- dependent degradation of ubiquitinated proteins are still poorly understood. Our recent studies defined several new ATP-dependent steps in this process. In coming years, we hope to learn how these various steps are regulated and coordinated to ensure efficient degradation of different types of proteins. After binding to the 26S, ubiquitin (Ub) conjugates activate their own degradation by stimulating ATP hydrolysis and gate opening via interactions with either of the 19S-associated deubiquitinating enzymes, Usp14 or Uch37. It will be important to understand further their regulatory roles, and how they coordinate substrate deubiquitination and proteolysis. Protein breakdown by the 26S is tightly linked to ATP hydrolysis, and we have shown that the six 19S ATPase subunits hydrolyze ATP in an ordered manner. We plan to critically test this novel cyclic mechanism and to learn if other AAA ATPases operate in a similar manner. We also recently found that prions (PrPSc) aggregates disrupt proteasome function by inhibiting gate opening and substrate entry into the 20S particle. We shall explore whether the soluble protein aggregates that appear to cause other neurodegenerative diseases cause a similar inhibition of proteasome gating. Related studies will explore how three newly discovered modifications of proteasome structure regulate 19S activity: 1) we recently found that the Ub-binding subunit Rpn13 is continually poly-ubiquitinated by 26S- associated Ub ligases, and that this modification inhibits conjugate degradation. 2) Upon excitatory stimulation of neurons, the ATPase subunit Rpt6 becomes phosphorylated, and this modification is important in synaptic plasticity. 3) The 19S caps on singly and doubly capped forms of the 26S proteasomes appear to differ in content of certain subunits. We hope to clarify the functional consequences of these intriguing proteasome modifications and learn how they influence different steps in conjugate degradation. Unlike mammalian cells, bacteria catalyze protein degradation by ubiquitin-independent, ATP-requiring protease complexes. Mycobacterium tuberculosis (Mtb) has two such ClpP genes and two regulatory AAA ATPases, ClpC1 and ClpX, which are all attractive new drug targets. We discovered that ClpP1 and ClpP2 encode a novel 2-ring complex, ClpP1P2, with a unique assembly mechanism. We now hope to solve its structure and define the detailed mechanisms of these two types of AAA ATPases and of the promising new antibiotic, Novo23, that we found uncouples ATP hydrolysis by ClpC1 from proteolysis by ClpP1P2. !

Public Health Relevance

The ubiquitin-proteasome system is the major pathway for protein degradation in eukaryotic cells and plays a critical role in eliminating misfolded and key regulatory proteins. The overall goal of our studies is to clarify the biochemical mechanisms by which the 26S proteasome catalyzes the rapid and efficient degradation of proteins tagged for degradation by the linkage to a chain of ubiquitin molecules. These studies are focusing on the roles of the proteasome-regulatory ATPases that bind protein substrates and translocate them into the 20S proteasome for degradation, but in addition, we are investigating a novel ATP-dependent proteolytic complex from Mycobacteria tuberculosis, ClpP1P2, which has unique biochemical properties and is a very attractive drug target.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Membrane Biology and Protein Processing (MBPP)
Program Officer
Wehrle, Janna P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Harvard Medical School
Anatomy/Cell Biology
Schools of Medicine
United States
Zip Code
Rock, Kenneth L; Farfán-Arribas, Diego J; Colbert, Jeff D et al. (2014) Re-examining class-I presentation and the DRiP hypothesis. Trends Immunol 35:144-52
Gavrish, Ekaterina; Sit, Clarissa S; Cao, Shugeng et al. (2014) Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem Biol 21:509-18
Besche, Henrike C; Sha, Zhe; Kukushkin, Nikolay V et al. (2014) Autoubiquitination of the 26S proteasome on Rpn13 regulates breakdown of ubiquitin conjugates. EMBO J 33:1159-76
Sha, Zhe; Goldberg, Alfred L (2014) Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97. Curr Biol 24:1573-83
Qian, Min-Xian; Pang, Ye; Liu, Cui Hua et al. (2013) Acetylation-mediated proteasomal degradation of core histones during DNA repair and spermatogenesis. Cell 153:1012-24
Nathan, James A; Kim, Hyoung Tae; Ting, Lily et al. (2013) Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes? EMBO J 32:552-65
Peth, Andreas; Nathan, James A; Goldberg, Alfred L (2013) The ATP costs and time required to degrade ubiquitinated proteins by the 26 S proteasome. J Biol Chem 288:29215-22
Peth, Andreas; Kukushkin, Nikolay; Bosse, Marc et al. (2013) Ubiquitinated proteins activate the proteasomal ATPases by binding to Usp14 or Uch37 homologs. J Biol Chem 288:7781-90
Nathan, James A; Spinnenhirn, Valentina; Schmidtke, Gunter et al. (2013) Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 152:1184-94
Raju, Ravikiran M; Unnikrishnan, Meera; Rubin, Daniel H F et al. (2012) Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathog 8:e1002511

Showing the most recent 10 out of 43 publications